Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

被引：40

作者：

Alosaimy, Sara ^{[1
]}

Jorgensen, Sarah C. J. ^{[1
,12
]}

Lagnf, Abdalhamid M. ^{[1
]}

Melvin, Sarah ^{[1
]}

Mynatt, Ryan P. ^{[2
,13
]}

Carlson, Travis J. ^{[3
,14
]}

Garey, Kevin W. ^{[3
]}

Allen, David ^{[4
]}

Venugopalan, Veena ^{[5
]}

Veve, Michael ^{[6
,7
]}

Athans, Vasilios ^{[8
]}

Saw, Stephen ^{[8
]}

Yost, Christine N. ^{[9
]}

Davis, Susan L. ^{[1
,10
]}

Rybak, Michael J. ^{[1
,2
,11
]}

机构：

[1] Wayne State Univ, Dept Pharm Practice, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI USA

[2] Detroit Med Ctr, Dept Pharm Serv, Detroit, MI USA

[3] Univ Houston, Coll Pharm, Houston, TX 77030 USA

[4] Inova Fairfax Med Campus, Dept Pharm, Falls Church, VA USA

[5] Univ Florida, Coll Pharm, Gainesville, FL USA

[6] Univ Tennessee, Coll Pharm, Knoxville, TN USA

[7] Univ Tennessee, Med Ctr, Knoxville, TN USA

[8] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[9] Beaumont Hosp, Royal Oak, MI USA

[10] Henry Ford Hosp, Dept Pharm, Detroit, MI 48202 USA

[11] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA

[12] Mt Sinai Hosp, Toronto, ON, Canada

[13] Univ Kentucky Healthcare, Lexington, KY USA

[14] High Point Univ, Fred Wilson Sch Pharm, High Point, NC USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 03期

关键词：

carbapenem-resistant Enterobacteriaceae; Gram-negative infections; meropenem-vaborbactam; multidrug-resistant; SEVERE SEPSIS;

D O I：

10.1093/ofid/ofaa051

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

引用

页数：4

共 50 条

[1] Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
Alosaimy, Sara
Lagnf, Abdalhamid M.
Morrisette, Taylor
Scipione, Marco R.
Zhao, Jing J.
Jorgensen, Sarah C. J.
Mynatt, Ryan
Carlson, Travis J.
Jo, Jinhee
Garey, Kevin W.
Allen, David
DeRonde, Kailynn
Vega, Ana D.
Abbo, Lilian M.
Venugopalan, Veena
Athans, Vasilios
Saw, Stephen
Claeys, Kimberly C.
Miller, Mathew
Molina, Kyle C.
Veve, Michael
Kufel, Wesley D.
Amaya, Lee
Yost, Christine
Ortwine, Jessica
Davis, Susan L.
Rybak, Michael J.
[J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (08):
[2] The Place of Meropenem-Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
Chopra, Teena
[J]. INFECTIOUS DISEASES AND THERAPY, 2021, 10 (02) : 633 - 635
[3] Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study
Zhang, Xiaojuan
Qi, Shaoyan
Duan, Xiaoguang
Han, Bing
Zhang, Shuguang
Liu, Shaohua
Wang, Haixu
Zhang, Haibo
Sun, Tongwen
[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
[4] Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study
Xiaojuan Zhang
Shaoyan Qi
Xiaoguang Duan
Bing Han
Shuguang Zhang
Shaohua Liu
Haixu Wang
Haibo Zhang
Tongwen Sun
[J]. Journal of Translational Medicine, 19
[5] Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria
Patel, Twisha S.
Pogue, Jason M.
Mills, John P.
Kaye, Keith S.
[J]. FUTURE MICROBIOLOGY, 2018, 13 (09) : 971 - 983
[6] Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections
Fornari, Chiara
Arrieta, Antonio
Bradley, John S.
Tout, Mira
Magalhaes, Paulo
Auriol, Faten Koraichi
Borella, Elisa
Piana, Chiara
Della Pasqua, Oscar
Vallespir, Bartomeu Piza
Mazzei, Paolo
Bokesch, Paula M.
Hoover, Randall
Capriati, Angela
Habboubi, Nassir
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (10) : 2597 - 2610
[7] Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
Zhang, Helen L.
Cressman, Leigh
Lautenbach, Ebbing
[J]. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 27 : 299 - 302
[8] Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
Morrisette, Taylor
Alosaimy, Sara
Lagnf, Abdalhamid M.
Frens, Jeremy J.
Webb, Andrew J.
Veve, Michael P.
Stevens, Ryan
Bouchard, Jeannette
Gore, Tristan W.
Ansari, Iman
Rybak, Michael J.
[J]. INFECTIOUS DISEASES AND THERAPY, 2022, 11 (04) : 1715 - 1723
[9] Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
Taylor Morrisette
Sara Alosaimy
Abdalhamid M. Lagnf
Jeremy J. Frens
Andrew J. Webb
Michael P. Veve
Ryan Stevens
Jeannette Bouchard
Tristan W. Gore
Iman Ansari
Michael J. Rybak
[J]. Infectious Diseases and Therapy, 2022, 11 : 1715 - 1723
[10] Real-world antibiotic needs for resistant Gram-negative infections
Fitzpatrick, Margaret A.
[J]. LANCET INFECTIOUS DISEASES, 2020, 20 (10): : 1108 - 1109

← 1 2 3 4 5 →